Navigation Links
Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
Date:10/1/2007

BETHESDA, Md., Oct. 2 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBT and NWBS) announced today that Anthony P. Deasey, 58, has been appointed as the Company's Senior Vice President of Finance and Chief Financial Officer, and has been elected to the Board of Directors.

Prior to joining NWBT, from November 2000 to September 2007 Mr. Deasey served as Executive Vice President, Chief Financial and Chief Operating Officer of Celsion Corporation, a biotechnology company headquartered in Columbia, Maryland. At Celsion, Mr. Deasey played a key role in transitioning Celsion from a medical device to an oncology drug development company, and acquired substantial experience with oncology regulatory and market factors. In addition to Celsion, Mr. Deasey previously served as Chief Financial Officer of two public companies with domestic and international operations and a diverse range of products with up to $800 million in revenues.

"We are very pleased to announce the appointment of Tony as our Chief Financial Officer," said Alton Boynton, PhD, President and Chief Executive Officer of Northwest Biotherapeutics. "As we are in the process of establishing international operations and accelerating our pivotal studies in the United States, Tony's extensive financial, operational and management experience, and his familiarity with the oncology sector, will be a valuable addition to our team."

ABOUT NORTHWEST BIOTHERAPEUTICS, INC.

Northwest Biotherapeutics, Inc. is a US-based biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, and on a cost-effective basis.

The Company has two lead product candidates:

1. DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of

Glioblastoma multiforme; and

2. DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment

of hormone independent, non-metastatic prostate cancer.

The Company also has a robust pipeline of additional products cleared by FDA for early stage clinical trials in five other cancers beyond brain and prostate cancers.

For further information, please visit the company web site at http://www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the uncertainties of litigation in general and, specifically litigation involving intellectual property claims and securities class action claims that have been filed against the Company. Additional information on these and other factors which could affect the company's results is included in its Securities and Exchange Commission ("SEC") filings and its filings pursuant to its listing on the Alternative Investment Market of the London Stock Exchange ("AIM"). Finally, there may be other factors not mentioned above or included in the company's SEC filings and/or AIM filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


'/>"/>
SOURCE Northwest Biotherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Northwestern Mutual, American Family make Computerworlds best IT workplaces
2. Northwestern adds to its Imago microscope
3. Imago microscope leads to Northwestern research advance
4. Northwest Wis. Manufacturing Outreach Center honored by DOC, NIST
5. Speaker announces business members of IT Task Force
6. Doyle announces technology tax credits for Berbee
7. Doyle announces new energy, global warming policies
8. Doyle announces $80M renewable energy strategy
9. GE announces first installation of Discovery VCT
10. UWM announces winners of RGI awards
11. Third Wave announces two senior management appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):